Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (19513)	4/23/1998 7:35:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

I believe you mean the second try for the NDA announcement and the LLY drug/cash decision.

To: Hippieslayer who wrote (19513)	4/23/1998 7:38:00 PM
From: Don S.Boller	Read Replies (1) \| Respond to of 32384

FUGAZI; ALSO, according to Mike Murphy - LGND is expected to file a NDA for Panretin Gel within the next six weeks.......... or did i miss that in trying to see through the smoke from the flames on this thread???? Best, to you, Don

To: Hippieslayer who wrote (19513)	4/23/1998 7:51:00 PM
From: Russian Bear	Read Replies (2) \| Respond to of 32384

Fugazi, <<I have doubts that the NDA announcement will severely influence the stock. Hope I'm wrong.>> <<On the Menu for lgnd is the NDA announcement and the LLY drug/cash decision.>> I have to agree with you. The NDA is widely expected, and I cannot see its announcement generating a lasting gain in the stock price (it has already been discounted, in all likelihood.) However, the LLY deal for the Seragen compound is another matter. Depending on the specifics of its ultimate resolution, this deal could significantly effect LGND, both near-term and longer-term. My own impression (just my perception, nothing more) is that this deal is currently viewed with some suspicion. A "neat" (read: easy to understand and with consequences that are easily projected) resolution would be a real positive for the stock, in my view. Mind you, what is best for the stock, near-term, may not always be best for the company, longer-term. With luck, these goals will coincide, in this instance. Regards, RB